Literature DB >> 23416067

BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells.

Fabian Vogt1, Justus Lieber, Alexander Dewerth, Alexander Hoh, Jörg Fuchs, Sorin Armeanu-Ebinger.   

Abstract

Advanced stages of tumour and development of metastases are the two major problems in treating liver tumours such as hepatoblastoma (HB) and hepatocellular carcinoma (HCC), in paediatric patients. Modulation of apoptosis in HB cells enhances the sensitivity of these cells towards various drugs and has been discussed to enforce treatment. We analysed the effect of apoptosis modulators, BH3 mimetics, on mechanisms of dissemination such as adhesion or migration of HB and HCC cells. BH3 mimetics such as ABT-737 and obatoclax can reduce cell migration in a scratch assay as well as adhesion of HB and HCC cells to matrigel. Immunofluorescence staining of F-actin demonstrated that development of lamellipodia, which are important for migration, decreased. BH3 mimetics increase the level of activated caspases 3 and 7 in HUH6 cells. This results in the degradation of GTPase Cdc42, which can be determined by western blot analysis. A pan-caspase inhibitor can block the migration and degradation of Rho-GTPase. In summary, our study showed that BH3 mimetics not only enhance drug sensitivity but also may prevent metastasis by inhibiting HB and HCC cell motility.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23416067     DOI: 10.1016/j.yexcr.2013.01.024

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

Review 1.  The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.

Authors:  Justus Lieber; Sorin Armeanu-Ebinger; Jörg Fuchs
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

Review 2.  Targeting BCL2-Proteins for the Treatment of Solid Tumours.

Authors:  Meike Vogler
Journal:  Adv Med       Date:  2014-08-27

3.  The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.

Authors:  Bin Wang; Zhenhong Ni; Xufang Dai; Liyan Qin; Xinzhe Li; Liang Xu; Jiqin Lian; Fengtian He
Journal:  Mol Cancer       Date:  2014-04-30       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.